Business Context and Reporting Period
Company: Universal Display Corporation (OLED)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A leader in OLED technologies and materials for display and lighting applications. Revenue is derived from material sales, royalty and license fees, and contract research services via its subsidiary, Adesis.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Total Revenue | $152,157 | $294,368 | $338,071 |
| Gross Margin | $115,367 (75.8%) | $221,457 (75.2%) | $260,734 (77.1%) |
| Operating Income | $53,648 | $96,399 | $138,204 |
| Net Income | $49,421 | $85,317 | $131,708 |
| Diluted EPS | $1.06 | $1.82 | $2.76 |
| Cash from Operations | N/A | $133,855 | $82,498 |
| Cash & Equivalents | $120,563 | $120,563 | $95,804 |
| Total Investments | $735,869 | $735,869 | $831,038 |
Note: Total Investments includes Short-term investments ($350.7M) and Long-term investments ($383.2M) as of June 30, 2026.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 11% year-over-year for the quarter and 13% for the six-month period. Material sales dropped 25% (QoQ) and 14% (YoY six-month) due to lower unit volumes and customer mix changes.
- License Fee Fluctuation: Royalty and license fees increased 7% in the quarter but decreased 9% for the six-month period. A $10.0 million cumulative catch-up adjustment (favorable) impacted the six-month 2026 results, offsetting some volume declines.
- Contract Research Services: Revenue from Adesis decreased 36% for both the quarter and six-month periods due to reduced specialty manufacturing demand.
- Profitability: Net income decreased 27% for the quarter and 35% for the six-month period. Gross margin percentage declined slightly to 75% from 77% in the prior year.
- Amortization Increase: Amortization of acquired technology increased significantly due to the January 2026 acquisition of the Merck KGaA patent portfolio ($50.0 million).
- Foreign Exchange Impact: The company recorded a $3.5 million foreign exchange loss for the six months ended June 30, 2026, compared to a $4.5 million gain in the prior year, driven by the Korean Won to U.S. Dollar fluctuation on a withholding tax receivable.
Guidance, Outlook, and Risks
- Capital Allocation: The Board authorized a new $400.0 million share repurchase program in April 2026. During the six months ended June 30, 2026, the company repurchased 1.16 million shares for $114.2 million. A quarterly dividend of $0.50 per share was declared for Q3 2026.
- Liquidity: The company holds $854.5 million in cash, cash equivalents, and investments. Management believes this is sufficient to meet obligations for at least the next twelve months.
- Strategic Acquisitions: Completed the acquisition of over 300 OLED-related patents from Merck KGaA in January 2026 for $50.0 million, amortized over 10 years.
- Key Risks:
- Customer Concentration: Three customers (A, B, and C) accounted for 85% of revenue for the six months ended June 30, 2026.
- Geographic Concentration: 97% of revenue is derived from outside North America, primarily South Korea and China.
- Tax Contingency: A significant Korean withholding tax receivable of $50.3 million is subject to ongoing litigation. A hearing scheduled for July 2026 was postponed pending information from the Korean Tax Authority.
- Patent Challenges: The company faces routine patent opposition proceedings globally as its portfolio expands.
Investor Verification Checklist
- Revenue Recognition Adjustments: Verify the impact of the $10.0 million cumulative catch-up adjustment on revenue estimates and future contract pricing.
- Korean Tax Receivable: Monitor the status of the $50.3 million Korean withholding tax receivable and the outcome of the postponed court hearing.
- Customer Demand Trends: Assess the sustainability of the decline in material sales volumes, particularly for red and green emitters.
- Amortization Impact: Confirm the long-term impact of the new Merck KGaA patent amortization on future operating margins.
- Share Repurchase Execution: Track the utilization of the new $400 million repurchase authorization and its effect on share count and EPS.